[PHARMA] Director RESIGNATION - ENCIK AHMAD SHAHREDZUAN BIN MOHD SHARIFF on 01-Oct-2024
Announcement Date
01-Oct-2024
Board Member Information:
Date of Change
01-Oct-2024
Type of Change
RESIGNATION
Reason
Appointed as the Chief Operating Officer of the Company
Designation
Director
Directorate
Non Independent and Non Executive
Age
41
Gender
Male
Nationality
Malaysia
Working Experience
February 2023 to September 2024 : Non-Independent Non-Executive Director, Pharmaniaga Berhad March 2021 to September 2024 : Group Chief Reinvention & Strategy Officer, Boustead Holdings Berhad (BHB) May 2020 to February 2021 : Chief Transformation Officer, (BHB) December 2019 to April 2020 : Senior General Manager, (BHB) June 2015 to November 2019 : Implementation Consultant, McKinsey & Company, Kuala Lumpur, Malaysia August 2006 to June 2015 : Various positions in Permodalan Nasional Berhad. Last position was Senior Manager at the Office of President and Group Chief Executive
Family Relationship
Nil
Conflict of Interest
Nil
Interest
Nil
Market Buzz
2024-10-01
2024-10-01
2024-10-01
2024-10-01
2024-10-01
2024-10-01
2024-10-01
2024-09-24
2024-09-24
2024-09-24
2024-09-23
2024-09-20
2024-09-20
2024-09-20
2024-09-20
2024-09-20
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
Latest Videos
.png)
MQ Trading Signals
Time
Signal
Duration
Type
2024-10-01 15:40:00
EMA 5
10 Mins
BUY
2024-10-01 15:40:00
EMA 5
5 Mins
BUY
2024-10-01 15:10:00
EMA 5
10 Mins
SELL
2024-10-01 15:05:00
EMA 5
5 Mins
SELL
2024-10-01 15:00:00
ADX
10 Mins
SELL
Apps
Top Articles
1
Mercury Securities Research
2
南洋 - 凭单专栏/温世麟
3
Stock Pick Contest Year 2024
4
5
6
Indexstockpedia
Malaysia Property Market Outlook and Top Small Cap Picks Edition
7
M+ Online Research Articles
8
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
